Cargando…
SUN-LB036 Diabetic Ketoacidosis: A Rare Side Effect of Nivolumab Induced Insulin Dependent Diabetes Mellitus
Introduction: Nivolumab, is a monoclonal antibody directed against programmed cell death-1 receptor (anti PD-1), and is used in adjuvant treatment of melanoma. With the widespread use of immunotherapies, the incidence of autoimmune diseases referred to as immune related adverse events (irAE) is also...
Autores principales: | Abid, Haisam, Watthanasuntorn, Kanramon, Gnanajothy, Rosana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553046/ http://dx.doi.org/10.1210/js.2019-SUN-LB036 |
Ejemplares similares
-
SUN-LB030 Empagliflozin Causing Euglycemic Diabetic Ketoacidosis
por: Thomas, Mathew, et al.
Publicado: (2019) -
SUN-LB025 Superior Mesenteric Artery Thrombosis: An Uncommon Complication of Diabetic Ketoacidosis
por: Saini, Khushpreet Kaur, et al.
Publicado: (2019) -
SUN-173 Nivolumab-Induced Fulminant Autoimmune Diabetes Presenting as Diabetic Ketoacidosis in a Patient with Melanoma
por: Parikh, Sahil, et al.
Publicado: (2019) -
SAT-LB118 Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Arao, Kevin A, et al.
Publicado: (2020) -
SUN-LB029 A Case of Gestational Diabetes with Diabetic Ketoacidosis, Insulin Injection Site Reaction and Anti Insulin Antibodies in Pregnancy
por: Hakimian, Stephanie, et al.
Publicado: (2019)